Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$238.675
Market cap
$35.07B
P/E Ratio
34.39
Dividend/share
$1.97
EPS
$6.94
Enterprise value
$35.7B
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea , chronic obstructive pulmonary disease , and other respiratory
Highlights
Resmed's debt has decreased by 45% YoY and by 25% QoQ
RMD's equity is up by 18% year-on-year and by 5% since the previous quarter
The price to earnings (P/E) is 24% higher than the last 4 quarters average of 27.6 but 23% lower than the 5-year quarterly average of 44.6
Resmed's quick ratio has decreased by 11% from the previous quarter and by 4.1% YoY
Key stats
What are the main financial stats of RMD
Market
Valuations
Earnings
Shares outstanding
146.93M
Market cap
$35.07B
Enterprise value
$35.7B
Price to earnings (P/E)
34.39
Price to book (P/B)
7.21
Price to sales (P/S)
7.49
EV/EBIT
27.24
EV/EBITDA
23.39
EV/Sales
7.62
Revenue
$4.69B
EBIT
$1.31B
EBITDA
$1.53B
Free cash flow
$1.3B
Per share
Balance sheet
Liquidity
EPS
$6.94
Free cash flow per share
$8.85
Book value per share
$33.11
Revenue per share
$31.87
TBVPS
$24.11
Total assets
$6.87B
Total liabilities
$2.01B
Debt
$873.94M
Equity
$4.86B
Working capital
$1.45B
Debt to equity
0.18
Current ratio
2.59
Quick ratio
1.18
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
32.6%
Gross margin
56.7%
Net margin
21.8%
Operating margin
28.2%
Return on assets
14.9%
Return on equity
22.4%
Return on invested capital
35.6%
Return on capital employed
22%
Return on sales
28%
Dividend yield
0.83%
DPS
$1.97
Payout ratio
28.4%
RMD stock price
How has the Resmed stock price performed over time
Intraday
0.31%
1 week
2.01%
1 month
-5.63%
1 year
65.48%
YTD
38.75%
QTD
-2.23%
Financial performance
How have Resmed's revenue and profit performed over time
Revenue
$4.69B
Gross profit
$2.66B
Operating income
$1.32B
Net income
$1.02B
Gross margin
56.7%
Net margin
21.8%
RMD's operating income is up by 17% YoY and by 9% QoQ
RMD's net income is up by 14% YoY and by 7% QoQ
The gross profit has grown by 13% YoY and by 3.8% from the previous quarter
The company's revenue rose by 11% YoY and by 2.2% QoQ
Growth
What is Resmed's growth rate over time
Valuation
What is Resmed stock price valuation
P/E
34.39
P/B
7.21
P/S
7.49
EV/EBIT
27.24
EV/EBITDA
23.39
EV/Sales
7.62
The price to earnings (P/E) is 24% higher than the last 4 quarters average of 27.6 but 23% lower than the 5-year quarterly average of 44.6
The EPS has increased by 13% YoY and by 6% from the previous quarter
RMD's P/B is 26% above its last 4 quarters average of 5.7 but 22% below its 5-year quarterly average of 9.2
RMD's equity is up by 18% year-on-year and by 5% since the previous quarter
The P/S is 31% higher than the last 4 quarters average of 5.7 but 11% lower than the 5-year quarterly average of 8.4
The company's revenue rose by 11% YoY and by 2.2% QoQ
Efficiency
How efficient is Resmed business performance
The company's return on invested capital rose by 19% YoY and by 11% QoQ
The ROA has increased by 6% from the previous quarter and by 4.9% YoY
Resmed's ROE has decreased by 5% YoY but it has increased by 2.3% from the previous quarter
The ROS has increased by 3.7% from the previous quarter and by 2.9% YoY
Dividends
What is RMD's dividend history
DPS
$1.97
Dividend yield
0.83%
Payout ratio
28.4%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Resmed financials performed over time
RMD's total liabilities is down by 23% year-on-year and by 8% since the previous quarter
The current ratio has contracted by 17% YoY and by 15% from the previous quarter
Resmed's debt is 82% lower than its equity
Resmed's debt to equity has shrunk by 53% YoY and by 28% QoQ
Resmed's debt has decreased by 45% YoY and by 25% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.